Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ARIAD Pharmaceuticals, Inc.
ARIAD Announces Court Rulings Regarding NF-kappaB Patent Lawsuit with Amgen
October 11th, 2008
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced that the United States District Court for the District of Delaware granted Amgen's (Nasdaq: AMGN) motion for summary judgment of non-infringement of seven claims of U.S. Patent No. 6,410,516 (the '516 patent) based on activities related to Enbrel(R) (etanercept). The court found that administration of Enbrel falls outside the scope of the asserted claims based on the court's interpretation of these claims to exclude extracellular methods of reducing NF-(kappa)B activity. "We are disappointed by these rulings on claim construction and noninfringment, and plan to pursue the appropriate legal action to obtain review of...
Source: Law & Health Weekly (2008-10-11)
|
